ACE2 and infection: To further confirm that the angiotensin IV–mediated enhancement of SARS-CoV-2 target cell entry occurs specifically during the viral entry phase, rather than as a result of post-entry modulation of reporter gene expression, we treated HEK293T-ACE2 cells with 40 nM angiotensin IV at 24 h post-infection, following viral removal and medium replacement (Figure 4C).